project id: TCGA-PRAD; case submitter id: TCGA-VN-A88M; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.98; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 0.97; rna integrity number: 7.8; age at index: 55; days to birth: -20157; ethnicity: not hispanic or latino; gender: male; race: black or african american; vital status: Alive; year of birth: 1958; age at diagnosis: 20157; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 189.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 288; initial weight: 60.0; sample id: 22803a08-1230-4246-88c2-e0e454e5d080; sample submitter id: TCGA-VN-A88M-01A; portion id: 349d61b2-dc72-4bfa-8ed8-3262dabcf0b4; portion submitter id: TCGA-VN-A88M-01A-11; slide id: 5c5ddfd6-febe-42b0-a80f-55dacb3be16d; slide submitter id: TCGA-VN-A88M-01A-01-TS1; percent lymphocyte infiltration: 60.0; percent monocyte infiltration: 10.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0; section location: TOP;